Baricitinib has shown superiority to Adalimumab in improving signs and symptoms of rheumatoid arthritis
Results of RA-BEAM, a phase 3 study of Baricitinib, in patients with moderately-to-severely active rheumatoid arthritis were announced.
The study met its primary objective of demonstrating superiorit ...
read article